Skip to content
10-Q

Quarterly Report

BioNexus Gene Lab Corp. BGLC

0001477932-25-003821

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 15, 2025 1.8M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $1.56M
Current Liabilities Q1 2025 · Dec 31, 2024 $1.95M
Total Liabilities Q1 2025 · Mar 31, 2025 $1.71M
Total Liabilities Q1 2025 · Dec 31, 2024 $2.11M
Current Assets Q1 2025 · Mar 31, 2025 $6.54M
Current Assets Q1 2025 · Dec 31, 2024 $7.43M
Total Assets Q1 2025 · Mar 31, 2025 $9.48M
Total Assets Q1 2025 · Dec 31, 2024 $10.43M
Shares Diluted Q1 2025 · Mar 31, 2024 17.67M sh
Capex Q1 2025 · Mar 31, 2024 $21.95K
Operating Cash Flow restated Q1 2025 · Mar 31, 2024 −$37.15K
Stockholders Equity Q1 2025 · Mar 31, 2024 $9.34M
Stockholders Equity Q1 2025 · Dec 31, 2023 $9.66M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.01
Sga Expense restated Q1 2025 · Mar 31, 2024 $315.79K
Rd Expense Q1 2025 · Mar 31, 2024 $11.48K
Net Income Q1 2025 · Mar 31, 2024 −$103.76K
Operating Income Q1 2025 · Mar 31, 2024 −$79.03K
Gross Profit Q1 2025 · Mar 31, 2024 $365.03K
Cost Of Revenue Q1 2025 · Mar 31, 2024 $2.02M
Revenue Q1 2025 · Mar 31, 2024 $2.38M